Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: determineeffectscellventricularheart
  Phrases that lowered it: myelomaprostatepatients wholaboratoryclinically
• Sponsor's past termination rate: 20.8% (raises risk) · Sponsor's track record
• Collaborators: 6 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 75 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 25.9% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 94.7% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 144 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma NCT01301807 · started 2011 · scored riskier than 92% of active trials completed
• Panobinostat/Velcade in Multiple Myeloma NCT00891033 · started 2009 · scored riskier than 63% of active trials terminated
• Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma NCT01083602 · started 2010 · scored riskier than 83% of active trials completed
• Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) NCT01651039 · started 2012 · scored riskier than 98% of active trials completed
• A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma NCT01965353 · started 2013 · scored riskier than 68% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.